Wire · opportunities
Tumor Treating Fields Extend Survival, but Uptake Has Been Slow
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
Tumor Treating Fields (TTF) have demonstrated extended overall survival in glioblastoma and other solid tumors with minimal side effects, but adoption remains slow due to limited awareness. The FDA has recently expanded approvals for TTF in cancers including glioblastoma, pancreatic cancer, non-small cell lung cancer, and mesothelioma.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You must educate your oncology networks on Tumor Treating Fields as recent approvals across multiple cancers create a market opening that remains underexploited. If you offer cancer treatment tech, this slow uptake is a clear opportunity to lead early adoption and capture clinical interest.
◆ Coverage
1 source · 31 Aug 2026
◆ Related on Wire
◆ Topics